While the early results appear promising, this remains a very small study with significant limitations that warrant caution. The trial included only 25 patients across two very different cancer types, lacked a control group, and had a median follow-up shorter than the reported survival times. More research is needed to understand why some patients benefit while others don't, and larger randomized trials are essential before drawing definitive conclusions about clinical utility.